BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34435978)

  • 1. Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma.
    Dong DN; Fan PW; Feng YN; Liu GH; Peng YC; Dong T; Wang RZ; Yu JM
    Chin Med J (Engl); 2021 Aug; 134(17):2066-2072. PubMed ID: 34435978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune profiling identifies CD8
    Chen Z; Guo ML; Li YY; Yan K; Li L; Shen F; Guan H; Liu QZ; Xu B; Lian ZX
    Front Immunol; 2022; 13():894919. PubMed ID: 36420264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
    Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
    Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
    Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal variation and prognostic significance of circulating immune cells in patients with nasopharyngeal carcinoma treated with chemoradiotherapy: a prospective cohort study.
    Huang C; Ding J; Huang C; Yu L; Chitapanarux I; Mejia MBA; Fei Z; Chen C
    Transl Cancer Res; 2023 Dec; 12(12):3718-3727. PubMed ID: 38192995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients.
    Shahbazi M; Moulana Z; Sepidarkish M; Bagherzadeh M; Rezanejad M; Mirzakhani M; Jafari M; Mohammadnia-Afrouzi M
    Microb Pathog; 2021 Apr; 153():104779. PubMed ID: 33548481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High proportion of circulating CD8 + CD28- senescent T cells is an independent predictor of distant metastasis in nasopharyngeal canrcinoma after radiotherapy.
    Xu X; Wei F; Xiao L; Wu R; Wei B; Huang S; Yi J; Cui W
    J Transl Med; 2023 Jan; 21(1):64. PubMed ID: 36721233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.
    Zhang Z; Huang J; Wang G; Jin F; Zheng J; Xiao H; Lei L; Luo J; Chen C
    BMC Cancer; 2020 Mar; 20(1):183. PubMed ID: 32131777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of Circulating Lymphocyte Subsets Before Treatment in Patients with Nasopharyngeal Carcinoma.
    Shen DS; Yan C; Liang Y; Chen KH; Zhu XD
    Cancer Manag Res; 2021; 13():8109-8120. PubMed ID: 34737639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden.
    van den Bulk J; van der Ploeg M; Ijsselsteijn ME; Ruano D; van der Breggen R; Duhen R; Peeters KCMJ; Fariña-Sarasqueta A; Verdegaal EME; van der Burg SH; Duhen T; de Miranda NFCC
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36792124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
    Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
    Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
    BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel EIF3C-related CD8
    Li R; Wang Y; Wen X; Cheng B; Lv R; Chen R; Hu W; Wang Y; Liu J; Lin B; Zhang H; Zhang E; Tang X
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):103. PubMed ID: 38400862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma].
    Hu QY; Liu P; Wang L; Fu ZF
    Ai Zheng; 2007 Apr; 26(4):394-7. PubMed ID: 17430659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
    PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
    Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
    BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma.
    Lu J; Chen XM; Huang HR; Zhao FP; Wang F; Liu X; Li XP
    Head Neck; 2018 Jun; 40(6):1245-1253. PubMed ID: 29493822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
    Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
    BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.